Literature DB >> 22318202

TCR affinity and specificity requirements for human regulatory T-cell function.

Gabriela Plesa1, Lingjie Zheng, Andrew Medvec, Caleph B Wilson, Camila Robles-Oteiza, Nathaniel Liddy, Alan D Bennett, Jessie Gavarret, Annelise Vuidepot, Yangbing Zhao, Bruce R Blazar, Bent K Jakobsen, James L Riley.   

Abstract

We investigated whether TCRs restricted to the more ubiquitously expressed MHC class I molecules could be used to redirect human regulatory T cells (Tregs). Using a series of HLA-A2-restricted TCRs that recognize the same peptide-MHC class I complex (pMHC) with affinities varying up to 3500 fold, we observed that TCR affinity had no effect on the ability of the introduced TCRs to confer potent Ag-specific suppressive activity. Surprisingly, we found a naturally occurring, low-affinity MHC class I-restricted TCR specific for an NY-ESO-1 epitope that was unable to redirect a functional CD4 T-effector cell response could confer potent antigen-specific suppressive activity when expressed in Tregs and severely impair the expansion of highly functional HIV-1(GAG)-specific CD8 T cells expressing a high-affinity TCR. This suppressive activity was only observed when both Ags were presented by the same cell, and no suppression was observed when the target Ags were put in distinct cells. These studies underscore the clinical utility of using MHC class I-restricted TCRs to endow Tregs with specificity to control autoimmune disease and highlight the conditions in which this approach would have most therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318202      PMCID: PMC3325034          DOI: 10.1182/blood-2011-09-377051

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells.

Authors:  Mindi R Walker; Bryan D Carson; Gerald T Nepom; Steven F Ziegler; Jane H Buckner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

2.  Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function.

Authors:  K Scott Weber; David L Donermeyer; Paul M Allen; David M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  BirA enzyme: production and application in the study of membrane receptor-ligand interactions by site-specific biotinylation.

Authors:  C A O'callaghan; M F Byford; J R Wyer; B E Willcox; B K Jakobsen; A J McMichael; J I Bell
Journal:  Anal Biochem       Date:  1999-01-01       Impact factor: 3.365

4.  Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.

Authors:  B L Levine; W B Bernstein; M Connors; N Craighead; T Lindsten; C B Thompson; C H June
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

5.  Directed evolution of human T-cell receptors with picomolar affinities by phage display.

Authors:  Yi Li; Ruth Moysey; Peter E Molloy; Anne-Lise Vuidepot; Tara Mahon; Emma Baston; Steven Dunn; Nathaniel Liddy; Jansen Jacob; Bent K Jakobsen; Jonathan M Boulter
Journal:  Nat Biotechnol       Date:  2005-02-20       Impact factor: 54.908

6.  Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells.

Authors:  Jeroen J A Coenen; Hans J P M Koenen; Esther van Rijssen; Luuk B Hilbrands; Irma Joosten
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

Review 7.  Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.

Authors:  Emma L Masteller; Qizhi Tang; Jeffrey A Bluestone
Journal:  Semin Immunol       Date:  2006-02-03       Impact factor: 11.130

Review 8.  Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.

Authors:  Shimon Sakaguchi; Masahiro Ono; Ruka Setoguchi; Haruhiko Yagi; Shohei Hori; Zoltan Fehervari; Jun Shimizu; Takeshi Takahashi; Takashi Nomura
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

9.  In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation.

Authors:  K E Earle; Q Tang; X Zhou; W Liu; S Zhu; M L Bonyhadi; J A Bluestone
Journal:  Clin Immunol       Date:  2005-04       Impact factor: 3.969

10.  Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia.

Authors:  Claudia R Ruprecht; Marco Gattorno; Francesca Ferlito; Andrea Gregorio; Alberto Martini; Antonio Lanzavecchia; Federica Sallusto
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

View more
  28 in total

1.  ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.

Authors:  Huanling Zhang; Yanyan Li; Xiaoping Liu; Zhaoduan Liang; Mengyong Yan; Qiang Liu; Anan Chen; Yifeng Bao; Chengzhi Zhou; Shiyue Li; Cassian Yee; Yi Li
Journal:  Immunology       Date:  2018-06-14       Impact factor: 7.397

2.  The Autoimmunity-Associated Gene CLEC16A Modulates Thymic Epithelial Cell Autophagy and Alters T Cell Selection.

Authors:  Cornelia Schuster; Kay D Gerold; Kilian Schober; Lilli Probst; Kevin Boerner; Mi-Jeong Kim; Anna Ruckdeschel; Thomas Serwold; Stephan Kissler
Journal:  Immunity       Date:  2015-05-12       Impact factor: 31.745

Review 3.  Autologous regulatory T cells for the treatment of type 1 diabetes.

Authors:  James A Thompson; Daniel Perry; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

4.  Strength of PD-1 signaling differentially affects T-cell effector functions.

Authors:  Fang Wei; Shi Zhong; Zhengyu Ma; Hong Kong; Andrew Medvec; Rafi Ahmed; Gordon J Freeman; Michelle Krogsgaard; James L Riley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

5.  Gut microbiota amplifies host-intrinsic conversion from the CD8 T cell lineage to CD4 T cells for induction of mucosal immune tolerance.

Authors:  Jen Bon Lui; Lander S McGinn; Zhibin Chen
Journal:  Gut Microbes       Date:  2016

6.  Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28.

Authors:  Chunjian Huang; Sunil Martin; Christian Pfleger; Jianguang Du; Jane H Buckner; Jeffrey A Bluestone; James L Riley; Steven F Ziegler
Journal:  J Immunol       Date:  2013-03-29       Impact factor: 5.422

7.  The protein tyrosine phosphatase PTPN22 controls forkhead box protein 3 T regulatory cell induction but is dispensable for T helper type 1 cell polarization.

Authors:  G Fousteri; T Jofra; I Debernardis; S M Stanford; A Laurenzi; N Bottini; M Battaglia
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

8.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

Review 9.  Restoring Regulatory T Cells in Type 1 Diabetes.

Authors:  Allyson Spence; Qizhi Tang
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

Review 10.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.